Edition:
United States

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

31.54USD
4:00pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$31.54
Open
$31.72
Day's High
$31.77
Day's Low
$31.50
Volume
398,506
Avg. Vol
1,475,771
52-wk High
$36.82
52-wk Low
$25.25

Latest Key Developments (Source: Significant Developments)

‍hoffmann-La Roche says Health Canada approved Ocrevus for treatment of adult patients with relapsing remitting multiple sclerosis​
Tuesday, 15 Aug 2017 08:00am EDT 

Aug 15 (Reuters) - Roche Holding Ag :‍hoffmann-La Roche Limited - Health Canada approved Ocrevus for treatment of adult patients with relapsing remitting multiple sclerosis​.  Full Article

Chugai Pharmaceutical to retire treasury shares
Tuesday, 25 Apr 2017 03:44am EDT 

April 25(Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it will retire 123,000 shares (0.02 percent of outstanding) of its common stock on April 28.  Full Article

Genentech announces positive interim results for Emicizumab in phase III study of children with Hemophilia A
Monday, 17 Apr 2017 01:00am EDT 

April 17 (Reuters) - :Genentech announces positive interim results for Emicizumab in phase III study of children with Hemophilia A.Genentech - results build upon data for Emicizumab in adults and adolescents with Hemophilia A and inhibitors to factor VIII.Genentech - Emicizumab Prophylaxis reduced number of bleeds in children with Hemophilia A and inhibitors to factor VIII.  Full Article

Genentech says FDA grants breakthrough therapy designation for Rituximab in Pemphigus Vulgaris
Friday, 24 Mar 2017 01:00am EDT 

Genentech: FDA grants breakthrough therapy designation for Rituxan (rituximab) in Pemphigus Vulgaris .U.S. Food and drug administration (fda) has granted breakthrough therapy designation status to Rituxan.  Full Article

Roche Diabetes Care signs exclusive agreement with Medtronic
Wednesday, 15 Feb 2017 02:06am EST 

Roche Holding Ag : Roche Diabetes Care signs exclusive agreement with Medtronic for bluetooth enabled blood glucose meters Further company coverage: [ROG.S] (Reporting by Zurich Newsroom) ((zurich.newsroom@thomsonreuters.com; +41 58 306 7336;)).  Full Article

CHMP recommends EU approval of Venclyxto in hard-to-treat CLL-Roche
Friday, 14 Oct 2016 07:16am EDT 

Roche Holding AG :Says : roche announces CHMP recommendation for eu approval of venclyxto for people with hard-to-treat chronic lymphocytic leukaemia.  Full Article

Roche receives 510(K) clearance from FDA for treponema pallidum assay
Monday, 26 Sep 2016 11:55am EDT 

Roche Holding Ag :Roche receives 510(K) clearance from FDA for Treponema Pallidum assay to aid Clinicians in the diagnosis of Syphilis infection.  Full Article

Transgenomic and Ventana Medical signs data sharing agreement
Thursday, 22 Sep 2016 08:11am EDT 

Transgenomic Inc :Says signed data sharing agreement with Ventana Medical Systems Inc, a subsidiary of Roche Holdings.  Full Article

Novimmune receives milestone payment from collaboration with Genentech
Monday, 5 Sep 2016 01:00am EDT 

Novimmune SA : Receives milestone payment from collaboration with Genentech . Under its agreement with Genentech, a member of Roche Group, a milestone triggering a payment has been achieved .Financial terms have not been disclosed.  Full Article

AbbVie initiates late stage study of venetoclax in patients with relapsed or refractory multiple myeloma
Thursday, 28 Jul 2016 05:30pm EDT 

Abbvie Inc : Venetoclax is being developed by abbvie and genentech, a member of roche group .Abbvie announces initiation of phase 3 study of venetoclax in patients with relapsed or refractory multiple myeloma.  Full Article

BRIEF-Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab

* Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab